Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
- PMID: 22152853
- PMCID: PMC3273723
- DOI: 10.1016/S0140-6736(11)61625-5
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
Abstract
Background: Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. We sought any such differences.
Methods: We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plus-anthracycline-based regimen versus the same, or more, non-taxane chemotherapy (n=44,000); one anthracycline-based regimen versus another (n=7000) or versus cyclophosphamide, methotrexate, and fluorouracil (CMF; n=18,000); and polychemotherapy versus no chemotherapy (n=32,000). The scheduled dosages of these three drugs and of the anthracyclines doxorubicin (A) and epirubicin (E) were used to define standard CMF, standard 4AC, and CAF and CEF. Log-rank breast cancer mortality rate ratios (RRs) are reported.
Findings: In trials adding four separate cycles of a taxane to a fixed anthracycline-based control regimen, extending treatment duration, breast cancer mortality was reduced (RR 0·86, SE 0·04, two-sided significance [2p]=0·0005). In trials with four such extra cycles of a taxane counterbalanced in controls by extra cycles of other cytotoxic drugs, roughly doubling non-taxane dosage, there was no significant difference (RR 0·94, SE 0·06, 2p=0·33). Trials with CMF-treated controls showed that standard 4AC and standard CMF were equivalent (RR 0·98, SE 0·05, 2p=0·67), but that anthracycline-based regimens with substantially higher cumulative dosage than standard 4AC (eg, CAF or CEF) were superior to standard CMF (RR 0·78, SE 0·06, 2p=0·0004). Trials versus no chemotherapy also suggested greater mortality reductions with CAF (RR 0·64, SE 0·09, 2p<0·0001) than with standard 4AC (RR 0·78, SE 0·09, 2p=0·01) or standard CMF (RR 0·76, SE 0·05, 2p<0·0001). In all meta-analyses involving taxane-based or anthracycline-based regimens, proportional risk reductions were little affected by age, nodal status, tumour diameter or differentiation (moderate or poor; few were well differentiated), oestrogen receptor status, or tamoxifen use. Hence, largely independently of age (up to at least 70 years) or the tumour characteristics currently available to us for the patients selected to be in these trials, some taxane-plus-anthracycline-based or higher-cumulative-dosage anthracycline-based regimens (not requiring stem cells) reduced breast cancer mortality by, on average, about one-third. 10-year overall mortality differences paralleled breast cancer mortality differences, despite taxane, anthracycline, and other toxicities.
Interpretation: 10-year gains from a one-third breast cancer mortality reduction depend on absolute risks without chemotherapy (which, for oestrogen-receptor-positive disease, are the risks remaining with appropriate endocrine therapy). Low absolute risk implies low absolute benefit, but information was lacking about tumour gene expression markers or quantitative immunohistochemistry that might help to predict risk, chemosensitivity, or both.
Funding: Cancer Research UK; British Heart Foundation; UK Medical Research Council.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3273723/bin/gr1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3273723/bin/gr2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3273723/bin/gr3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3273723/bin/gr4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3273723/bin/gr5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3273723/bin/gr6.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3273723/bin/gr7.gif)
Comment in
-
The 2011 EBCTCG polychemotherapy overview.Lancet. 2012 Feb 4;379(9814):390-2. doi: 10.1016/S0140-6736(11)61823-0. Epub 2011 Dec 5. Lancet. 2012. PMID: 22152852 No abstract available.
-
ACP Journal Club. Individual patient meta-analysis: taxane plus anthracycline reduces mortality from early breast cancer.Ann Intern Med. 2012 Jun 19;156(12):JC6-4. doi: 10.7326/0003-4819-156-12-201206190-02004. Ann Intern Med. 2012. PMID: 22711105 No abstract available.
Similar articles
-
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005 May 14-20;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0. Lancet. 2005. PMID: 15894097
-
Multi-agent chemotherapy for early breast cancer.Cochrane Database Syst Rev. 2002;(1):CD000487. doi: 10.1002/14651858.CD000487. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD000487. doi: 10.1002/14651858.CD000487.pub2. PMID: 11869577 Updated. Review.
-
WITHDRAWN: Multi-agent chemotherapy for early breast cancer.Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD000487. doi: 10.1002/14651858.CD000487.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843612 Free PMC article. Review.
-
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.Lancet. 1998 Sep 19;352(9132):930-42. Lancet. 1998. PMID: 9752815
Cited by
-
Predictive Factors of Neoadjuvant Chemotherapy Response in Breast Cancer Validated by Three Anatomopathological Scores: Residual Cancer Burden, Chevallier System, and Tumor-Infiltrating Lymphocytes.Cureus. 2024 Apr 30;16(4):e59391. doi: 10.7759/cureus.59391. eCollection 2024 Apr. Cureus. 2024. PMID: 38817506 Free PMC article.
-
CSCO breast cancer management guidelines 2022: Australian perspective.Transl Breast Cancer Res. 2022 Oct 31;3:36. doi: 10.21037/tbcr-22-46. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751522 Free PMC article. No abstract available.
-
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients.NPJ Breast Cancer. 2024 May 15;10(1):36. doi: 10.1038/s41523-024-00642-6. NPJ Breast Cancer. 2024. PMID: 38750090 Free PMC article.
-
Proteogenomic characterization of difficult-to-treat breast cancer with tumor cells enriched through laser microdissection.Breast Cancer Res. 2024 May 14;26(1):76. doi: 10.1186/s13058-024-01835-4. Breast Cancer Res. 2024. PMID: 38745208 Free PMC article.
-
Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients.J Transl Med. 2024 Apr 29;22(1):398. doi: 10.1186/s12967-024-05088-9. J Transl Med. 2024. PMID: 38685030 Free PMC article.
References
-
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
-
- Early Breast Cancer Trialists' Collaborative Group . Treatment of early breast cancer: worldwide evidence, 1985–1990. Oxford University Press; Oxford: 1990. Introduction and methods.http://www.ctsu.ox.ac.uk/reports/ebctcg-1990/index_html (accessed May 20, 2011).
-
- Dowsett M, Cuzick J, Ingle J. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors vs tamoxifen. J Clin Oncol. 2010;28:509–518. - PubMed
-
- Engelsman E, Klijn JCM, Rubens RD. ‘Classical’ CMF vs a 3-weekly intravenous CMF schedule. Eur J Cancer. 1991;27:966–970. - PubMed
Uncited reference
-
- Straver ME, Glas AM, Hannemann J. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119:551–558. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical